喷雾剂临床应用及质量控制研究进展

张鹰楠; 许子艺; 卢光照; 鲁莹; 张翮; 张鹰楠; 许子艺; 卢光照; 鲁莹; 张翮

doi:10.12206/j.issn.2097-2024.202306047

[1]

SHRESTHA K, VAN STRIEN J, SINGH N, et al. Primary break-up and atomization characteristics of a nasal spray[J]. PLoS One, 2020, 15(8):e0236063. doi: 10.1371/journal.pone.0236063

[2]

CHENG Y S. Mechanisms of pharmaceutical aerosol deposi-tion in the respiratory tract[J]. AAPS PharmSciTech, 2014, 15(3):630-640. doi: 10.1208/s12249-014-0092-0

[3]

SOUDRY E, WANG J, VAEZEAFSHAR R, et al. Safety analysis of long-term budesonide nasal irrigations in patients with chronic rhinosinusitis post endoscopic sinus surgery[J]. Int Forum Allergy Rhinol, 2016, 6(6):568-572. doi: 10.1002/alr.21724

[4]

王凯, 孔慧霞, 刘静炎, 等. 重组人干扰素α-2b喷雾剂联合热毒宁治疗小儿手足口病的疗效分析[J]. 中华全科医学, 2020, 18(4):561-563,567.

[5]

陈建军, 殷善开, 刘世喜, 等. 冰连清咽喷雾剂治疗急性咽炎及慢性咽炎急性发作多中心随机对照研究[J]. 临床耳鼻咽喉头颈外科杂志, 2018, 32(1):1-6.

[6]

李红, 鄢素琪, 邓玉萍, 等. 喜炎平注射液联合开喉剑喷雾剂治疗小儿疱疹性咽峡炎疗效观察[J]. 中国医院药学杂志, 2014, 34(11):923-926.

[7]

万妮, 陈斌, 李合, 等. 肺部吸入给药系统的研究进展[J]. 中国新药杂志, 2021, 30(15):1386-1395.

[8]

LEYVA-GRADO V H, TAN G S, LEON P E, et al. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies[J]. Antimicrob Agents Chemother, 2015, 59(7):4162-4172. doi: 10.1128/AAC.00290-15

[9]

VAN HEEKE G, ALLOSERY K, DE BRABANDERE V, et al. Nanobodies®Nanobody is a registered trademark of Ablynx NV. as inhaled biotherapeutics for lung diseases[J]. Pharmacol Ther, 2017, 169:47-56.

[10]

HASSAN A O, KAFAI N M, DMITRIEV I P, et al. A single-dose intranasal ChAdvaccine protects upper and lower respirato-ry tracts against SARS-CoV-2[J]. Cell, 2020, 183(1): 169-184. e13.

[11]

CHEN J Y, WANG P, YUAN L Z, et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2[J]. Sci Bull, 2022, 67(13):1372-1387. doi: 10.1016/j.scib.2022.05.018

[12]

ZHU F C, ZHUANG C L, CHU K, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials[J]. Lancet Respir Med, 2022, 10(8):749-760. doi: 10.1016/S2213-2600(22)00131-X

[13]

LI Y, FAN X P, LI W Q, et al. Metoclopramide nasal spray in vitro evaluation and in vivo pharmacokinetic studies in dogs[J]. Pharm Dev Technol, 2018, 23(3):275-281. doi: 10.1080/10837450.2017.1316734

[14]

MATTSSON L A, CHRISTIANSEN C, COLAU J C, et al. Clinical equivalence of intranasal and oral 17β-estradiol for postmenopausal symptoms[J]. Am J ObstetGynecol, 2000, 182(3):545-552. doi: 10.1067/mob.2000.104843

[15]

COHN J A, KOWALIK C G, REYNOLDS W S, et al. Desmopressin acetate nasal spray for adults with nocturia[J]. Expert Rev Clin Pharmacol, 2017, 10(12):1281-1293. doi: 10.1080/17512433.2017.1394185

[16]

KAMINETSKY J, FEIN S, DMOCHOWSKI R, et al. Efficacy and safety of SER120 nasal spray in patients with nocturia: pooled analysis of 2 randomized, double-blind, placebo controlled, phase 3 trials[J]. J Urol, 2018, 200(3):604-611. doi: 10.1016/j.juro.2018.04.050

[17]

ROY A, THULASIRAMAN S, PANNEERSELVAM E, et al. Evaluation of the efficacy of salmon calcitonin nasal spray on bone healing following open reduction and internal fixation of mandibular fractures - A randomized controlled trial[J]. J CraniomaxillofacSurg, 2021, 49(12):1151-1157. doi: 10.1016/j.jcms.2021.08.002

[18]

BALFOUR J A, HEEL R C. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints[J]. Drugs, 1990, 40(4):561-82. doi: 10.2165/00003495-199040040-00006

[19]

FRASER I S, WEISBERG E, KUMAR N, et al. An initial pharmacokinetic study with a Metered Dose Transdermal System® for delivery of the progestogen Nestorone® as a possible future contraceptive[J]. Contraception, 2007, 76(6):432-438. doi: 10.1016/j.contraception.2007.08.006

[20]

ZECH J, DZIKOWSKI R, SIMANTOV K, et al. Transdermal delivery of artemisinins for treatment of pre-clinical cerebral malaria[J]. Int J Parasitol, 2021, 16:148-154.

[21]

KUCHARZEWSKI M, ROJCZYK E, WILEMSKA-KUCHARZEWSKA K, et al. Novel trends in application of stem cells in skin wound healing[J]. Eur J Pharmacol, 2019, 843:307-315. doi: 10.1016/j.ejphar.2018.12.012

[22]

ESTEBAN-VIVES R, CORCOS A, CHOI M S, et al. Cell-spray auto-grafting technology for deep partial-thickness burns: problems and solutions during clinical implementation[J]. Burns, 2018, 44(3):549-559. doi: 10.1016/j.burns.2017.10.008

[23]

GERLACH J, JOHNEN C, OTTOMAN C, et al. Method for autologous single skin cell isolation for regenerative cell spray transplantation with non-cultured cells[J]. Int J Artif Organs, 2011, 34(3):271-279. doi: 10.5301/IJAO.2011.6508

[24]

KYM D, YIM H, YOON J, et al. The application of cultured epithelial autografts improves survival in burns[J]. Wound Repair Regen, 2015, 23(3):340-344. doi: 10.1111/wrr.12279

[25]

JIN X, FU Q, GU Z H, et al. Chitosan/PDLLA-PEG-PDLLA solution preparation by simple stirring and formation into a hydrogel at body temperature for whole wound healing[J]. Int J BiolMacromol, 2021, 184:787-796. doi: 10.1016/j.ijbiomac.2021.06.087

[26]

TAVAKOLI S, MOKHTARI H, KHARAZIHA M, et al. A multifunctional nanocomposite spray dressing of Kappa-carrageenan-polydopamine modified ZnO/L-glutamic acid for diabetic wounds[J]. Mater SciEng C, 2020, 111:110837. doi: 10.1016/j.msec.2020.110837

[27]

LIU Z W, TANG W Z, LIU J Y, et al. A novel sprayablethermosensitive hydrogel coupled with zinc modified metformin promotes the healing of skin wound[J]. Bioact Mater, 2022, 20:610-626.

[28]

DE MELO BA G, JODAT Y A, CRUZ E M, et al. Strategies to use fibrinogen as bioink for 3D bioprinting fibrin-based soft and hard tissues[J]. ActaBiomater, 2020, 117:60-76.

[29]

VEAZEY W S, ANUSAVICE K J, MOORE K. Mammalian cell delivery via aerosol deposition[J]. J Biomed Mater Res, 2005, 72B(2):334-338. doi: 10.1002/jbm.b.30159

[30]

WHITEFORD H A, FERRARI A J, DEGENHARDT L, et al. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010[J]. PLoS One, 2015, 10(2):e0116820. doi: 10.1371/journal.pone.0116820

[31]

PFEFFERBAUM B, NORTH C S. Mental health and the covid-19 pandemic[J]. N Engl J Med, 2020, 383(6):510-512. doi: 10.1056/NEJMp2008017

[32]

PARDRIDGE W M. The blood-brain barrier: bottleneck in brain drug development[J]. NeuroRx, 2005, 2(1):3-14. doi: 10.1602/neurorx.2.1.3

[33]

PROFACI C P, MUNJI R N, PULIDO R S, et al. The blood-brain barrier in health and disease: important unanswered questions[J]. J Exp Med, 2020, 217(4):e20190062. doi: 10.1084/jem.20190062

[34]

MISRA A, JOGANI V, JINTURKAR K, et al. Recent patents review on intranasal administration for CNS drug delivery[J]. Recent Pat Drug DelivFormul, 2008, 2(1):25-40. doi: 10.2174/187221108783331429

[35]

LANDIS M S, BOYDEN T, PEGG S. Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective[J]. Ther Deliv, 2012, 3(2):195-208.

[36]

PARDESHI C V, BELGAMWAR V S. Direct nose to brain drug delivery viaintegrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting[J]. Expert Opin Drug Deliv, 2013, 10(7):957-972. doi: 10.1517/17425247.2013.790887

[37]

DUFES C, OLIVIER J C, GAILLARD F, et al. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats[J]. Int J Pharm, 2003, 255(1-2):87-97. doi: 10.1016/S0378-5173(03)00039-5

[38]

AGARWAL S K, KRIEL R L, BRUNDAGE R C, et al. A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers[J]. Epilepsy Res, 2013, 105(3):362-367. doi: 10.1016/j.eplepsyres.2013.02.018

[39]

DIETRICH E, GUMS J G. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain[J]. Ann Pharmacother, 2012, 46(10):1382-1391. doi: 10.1345/aph.1R069

[40]

BOUW M R, CHUNG S S, GIDAL B, et al. Clinical pharmacokinetic and pharmacodynamic profile of midazolam nasal spray[J]. Epilepsy Res, 2021, 171:106567. doi: 10.1016/j.eplepsyres.2021.106567

[41]

KATZ E G, HOUGH D, DOHERTY T, et al. Benefit-risk assessment of esketaminenasal spray vs. placebo in treatment-resistant depression[J]. Clin Pharmacol Ther, 2021, 109(2):536-546.

[42]

WEN Y, ZHANG Z X, CAI Z M, et al. Ligustrazine-loaded borneolliposome alleviates cerebral ischemia–reperfusion injury in rats[J]. ACS BiomaterSciEng, 2022, 8(11):4930-4941.

[43]

WINGROVE J, SWEDROWSKA M, SCHERLIEß R, et al. Characterisation of nasal devices for delivery of insulin to the brain and evaluation in humans using functional magnetic resonance imaging[J]. J Control Release, 2019, 302:140-147. doi: 10.1016/j.jconrel.2019.03.032

[44]

SHPAKOV A O, ZORINA I I, DERKACH K V. Hot spots for the use of intranasal insulin: cerebral ischemia, brain injury, diabetes mellitus, endocrine disorders and postoperative delirium[J]. Int J MolSci, 2023, 24(4):3278.

[45]

冯松浩, 许浚, 王月红, 等. 中药喷雾剂的研究进展及在产品开发中的应用[J]. 中草药, 2017, 48(5):1037-1044.

[46]

LI B V, JIN F Y, LEE S L, et al. Bioequivalence for locally acting nasal spray and nasal aerosol products: standard development and generic approval[J]. AAPS J, 2013, 15(3):875-883. doi: 10.1208/s12248-013-9494-2

[47]

GRMAŠ J, STARE K, BOŽIČ D, et al. Elucidation of formulation and delivery device-related effects on in vitro performance of nasal spray with implication to rational product specification identification[J]. J Aerosol Med Pulm Drug Deliv, 2017, 30(4):230-246. doi: 10.1089/jamp.2016.1328

[48]

GRMAŠ J, DREU R, INJAC R. Analytical challenges of spray pattern method development for purposes of in vitro bioequivalence testing in the case of a nasal spray product[J]. J Aerosol Med Pulm Drug Deliv, 2019, 32(4):200-212. doi: 10.1089/jamp.2018.1473

[49]

CALMET H, OKS D, SANTIAGO A, et al. Validation and Sensitivity analysis for a nasal spray deposition computational model[J]. Int J Pharm, 2022, 626:122118. doi: 10.1016/j.ijpharm.2022.122118

[50]

KOLANJIYIL A V, WALENGA R, BABISKIN A, et al. Establishing quantitative relationships between changes in nasal spray in vitro metrics and drug delivery to the posterior nasal region[J]. Int J Pharm, 2023, 635:122718. doi: 10.1016/j.ijpharm.2023.122718

[51]

FOO M Y, SAWANT N, OVERHOLTZER E, et al. A simplified geometric model to predict nasal spray deposition in children and adults[J]. AAPS PharmSciTech, 2018, 19(7):2767-2777. doi: 10.1208/s12249-018-1031-2

[52]

FOO M Y, CHENG Y S, SU W C, et al. The influence of spray properties on intranasal deposition[J]. J Aerosol Med, 2007, 20(4):495-508. doi: 10.1089/jam.2007.0638

[53]

BAXTER S, MYATT B, STEIN S, et al. Spray pattern and plume geometry testing and methodology: an IPAC-RS working group overview[J]. AAPS PharmSciTech, 2022, 23(5):145. doi: 10.1208/s12249-022-02278-w

[54]

GUO C N, STINE K J, KAUFFMAN J F, et al. Assessment of the influence factors on in vitro testing of nasal sprays using Box-Behnken experimental design[J]. Eur J Pharm Sci, 2008, 35(5):417-426. doi: 10.1016/j.ejps.2008.09.001

[55]

PENNINGTON J, PANDEY P, TAT H, et al. Spray pattern and droplet size analyses for high-shear viscosity determination of aqueous suspension corticosteroid nasal sprays[J]. Drug Dev Ind Pharm, 2008, 34(9):923-929. doi: 10.1080/03639040802149046

[56]

JENNY KWONG W T, HO S L, COATES A L. Comparison of nebulized particle size distribution with malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow marple personal cascade impactor[J]. J Aerosol Med, 2000, 13(4):303-314. doi: 10.1089/jam.2000.13.303

[57]

SHEKUNOV B Y, CHATTOPADHYAY P, TONG H H Y, et al. Particle size analysis in pharmaceutics: principles, methods and applications[J]. Pharm Res, 2007, 24(2):203-227. doi: 10.1007/s11095-006-9146-7

[58]

INTHAVONG K, FUNG M C, YANG W, et al. Measurements of droplet size distribution and analysis of nasal spray atomization from different actuation pressure[J]. J Aerosol Med Pulm Drug Deliv, 2015, 28(1):59-67. doi: 10.1089/jamp.2013.1093